Currently, there are 53.46M common shares owned by the public and among those 52.90M shares have been available to trade.
The company’s stock has a 5-day price change of -19.59% and 115.68% over the past three months. MIST shares are trading 7.59% year to date (YTD), with the 12-month market performance down to -33.90% lower. It has a 12-month low price of $0.63 and touched a high of $2.75 over the same period. MIST has an average intraday trading volume of 1.05 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -18.00%, -3.75%, and -7.59% respectively.
Institutional ownership of Milestone Pharmaceuticals Inc (NASDAQ: MIST) shares accounts for 22.27% of the company’s 53.46M shares outstanding.
It has a market capitalization of $83.40M and a beta (3y monthly) value of 0.54. The earnings-per-share (ttm) stands at -$0.83. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.52% over the week and 7.77% over the month.
Earnings per share for the fiscal year are expected to decrease by -20.52%, and -6.09% over the next financial year. EPS should shrink at an annualized rate of 9.29% over the next five years, compared to 28.21% over the past 5-year period.
Looking at the support for the MIST, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on June 05, 2025, with the firm’s price target at $5. Rodman & Renshaw coverage for the Milestone Pharmaceuticals Inc (MIST) stock in a research note released on August 22, 2024 offered a Buy rating with a price target of $9. Jefferies was of a view on June 20, 2023 that the stock is Hold, while Piper Sandler gave the stock Overweight rating on April 22, 2022, issuing a price target of $8- $10. H.C. Wainwright on their part issued Buy rating on March 05, 2021.
